Sorrento intends to combine a variety of its proprietary mAbs in conjunction with the ADNAB technology platform... Apr 28
In this study, the addition of nelonemdaz to surgical blood clot removal improved a patient’s chances of returning to functional independence 90 days later.... Oct 15
-Advertisements-